E2Z Stock Chart & Stats
€10.44
-€0.05(-0.55%)
At close: 4:00 PM EST
€10.44
-€0.05(-0.55%)
Day’s Range― - ―
52-Week Range€10.04 - €13.72
Previous CloseN/A
Volume510.00
Average Volume (3M)118.00
Market Cap
€2.19B
Enterprise Value€2.41B
Total Cash (Recent Filing)€355.41M
Total Debt (Recent Filing)€363.67M
Price to Earnings (P/E)30.4
Beta0.63
Next Earnings
Nov 09, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.33
Shares Outstanding217,777,330
10 Day Avg. Volume100
30 Day Avg. Volume118
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.85
Price to Sales (P/S)2.49
P/FCF Ratio20.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.39
Revenue Forecast (FY)€1.23B
Bulls Say, Bears Say
Bulls Say
Revenue And Profit RecoveryThe sharp TTM revenue acceleration and return to profitability indicate improved commercial performance across Almirall’s business. If sustained, stronger sales and positive earnings can support reinvestment in dermatology products, geographic expansion, and lifecycle management.
Conservative Balance SheetDeclining leverage and growing equity provide Almirall with greater financial resilience and flexibility. A conservative balance sheet can help the company fund product development, partnerships, and commercial initiatives while reducing pressure from debt obligations during periods of earnings volatility.
Stronger Cash GenerationThe substantial TTM operating and free cash flow improvement strengthens Almirall’s ability to finance operations internally. Greater cash generation can support investment in its dermatology portfolio, reduce reliance on external funding, and improve flexibility in allocating capital.
Bears Say
Earnings VolatilityThe uneven multi-year earnings record reduces confidence that the recent profit recovery will be durable. Continued volatility could make it harder to plan investment, assess sustainable earnings power, and consistently fund growth initiatives from internally generated profits.
Inconsistent Cash Flow QualityAlthough TTM cash generation is strong, prior negative or breakeven periods show that conversion has not been consistently dependable. This inconsistency may constrain the company’s ability to maintain investment and shareholder distributions through weaker operating periods.
Low Returns On CapitalReturns of roughly 4.8% remain modest relative to Almirall’s capital base, particularly after several weak prior years. Unless profitability improves further, the company may generate limited economic value from its equity and have less capacity to compound shareholder returns.
Almirall News
E2Z FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest stock price was €10.04 and its highest was €13.72 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is €2.19B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is Nov 09, 2026 which is in 28 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on Jul 24, 2026. The company reported €0.12 earnings per share for the quarter, missing the consensus estimate of €0.13 by -€0.01.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Overvalued.
Does Almirall SA pay dividends?
Almirall SA does not currently pay dividends.
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate is 0.08.
How many shares outstanding does Almirall SA have?
Almirall SA has 217,777,330 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of €0.12 in its last earnings report, missing expectations of €0.13. Following the earnings report the stock price went up 1.468%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in DE:E2Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-14.65%
12-Months-Change
Fundamentals
Return on Equity
4.78%
Trailing 12-Months
Asset Growth
2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Almirall SA
Almirall, S.A. is a biopharmaceutical firm dedicated to the discovery, development, production, and commercialization of treatments primarily focused on skin health. Operating globally, with a significant presence in Europe and the United States, its product line targets various dermatological ailments such as actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, alongside rare skin conditions. Beyond its core dermatology focus, the company also offers solutions for cardiovascular, musculoskeletal, respiratory, and nervous system disorders, as well as products for digestive health, anti-infectives for systemic use, genitourinary conditions and sex hormones, immunostimulants, and systemic hormonal preparations. Its extensive portfolio includes a range of well-known medications, such as Ilumetri, Solaraze, Skilarence, and Klisyri, among others. Almirall fosters strategic partnerships with numerous entities to advance its pipeline, including research institutions like the University of Dundee and commercial partners such as Eli Lilly and Company. Founded in Barcelona, Spain, in 1943, the company adopted its current name, Almirall, S.A., in May 2009, having previously been known as Laboratorios Almirall, S.A.